TLR4/MD-2 senses lipid A, activating the MyD88-signaling pathway on the plasma membrane and the TRIF-signaling pathway after CD14-mediated TLR4/MD-2 internalization into endosomes. Monophosphoryl lipid A (MPL), a detoxified derivative of lipid A, is weaker than lipid A in activating the MyD88-dependent pathway. Little is known, however, about mechanisms underlying the attenuated activation of MyD88-dependent pathways. We here show that MPL was impaired in induction of CD14-dependent TLR4/MD-2 dimerization compared with lipid A. Impaired TLR4/MD-2 dimerization decreased CD14-mediated TNFα production. In contrast, MPL was comparable to lipid A in CD14-independent MyD88-dependent TNFα production and TRIF-dependent responses including cell surface CD86 up-regulation and IFNβ induction. Although CD86 up-regulation is dependent on TRIF signaling, it was induced by TLR4/MD-2 at the plasma membrane. These results revealed that the attenuated MPL responses were due to CD14-initiated responses at the plasma membrane, but not just to responses initiated by MyD88, that is, MPL was specifically unable to induce CD14-dependent TLR4/MD-2 dimerization that selectively enhances MyD88-mediated responses at the plasma membrane.
Introduction
LPS, a principal membrane component of Gram-negative bacteria, has a robust immunostimulating activity. LPSbinding protein (LBP) extracts monomeric LPS from the microbial membrane and transfers it to CD14, which is a major plasma membrane-bound modulator for LPS loading to TLR4/ MD-2 (1) (2) (3) (4) . LPS interacts with the hydrophobic pocket of MD-2, which is constitutively associated with the TLR4 ectodomain (5-7). The ligand-loaded MD-2 interacts with another site of the TLR4 ectodomain of another TLR4/MD-2, leading to TLR4/MD-2 dimerization (6) . The phenylalanine at position 126 (F126) of MD-2 resides juxta-interface of the TLR4/MD-2 dimer and is specifically required for TLR4/MD-2 dimerization but not for interaction with LPS (7, 8) . LPS responses are dependent on dimerization of TLR4/MD-2, not of TLR4 alone.
LPS-activated TLR4/MD-2 induces a variety of immune responses, such as pro-inflammatory cytokine production, type I IFN production, and acquired immune responses through two distinct signaling cascades, MyD88-and TRIFdependent pathways. The MyD88-dependent pathway is activated at the plasma membrane (9, 10) , and the TRIFdependent pathway is activated after TLR4/MD-2 is internalized into endosomes (11, 12) . Recruitment of MyD88 and TRIF to the TLR4/MD-2 dimer requires sorting adaptor proteins, Toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) (9) and TRIF-related adaptor molecule (TRAM) (11, 12) , respectively. Production of inflammatory cytokines requires both signaling pathways, whereas the MyD88-dependent pathway is not essential for induction of IFNβ and up-regulation of a co-stimulatory molecule CD86 (13) . Cell surface CD14 enhances MyD88-dependent LPS responses (14) and is indispensable for TRIF-dependent responses in endosomes by controlling TLR4/MD-2 internalization (2, 15) .
Monophosphoryl lipid A (MPL) is known as one of the artificially detoxified derivatives of lipid A. With its detoxified feature, 308 CD14-independent TLR4 activation on the cell surface MPL has been used as a component of vaccination adjuvants. Previous studies on its low toxicity (16) (17) (18) (19) suggest that MPL induces inefficient receptor dimerization and hypoactivation of MyD88-dependent signaling. In contrast, MPL is comparable to lipid A in the activation of TRIF-dependent signaling.
To further understand the mechanism underlying MPL responses, we here compared lipid A and MPL with regard to TLR4/MD-2 dimerization by biochemical analyses. We found that MPL was much weaker than lipid A in inducing TLR4/MD-2 dimerization. Impaired TLR4/MD-2 dimerization correlated with a decrease of CD14-dependent TNFα production, but not with CD14-independent TNFα production, CD14-dependent IFNβ induction and CD14-independent CD86 up-regulation. These results suggested that the low toxicity of MPL is ascribed to the lack of CD14-initiated MyD88-mediated responses at the plasma membrane.
Methods

Mice
Age-and sex-matched 7-to 13-week-old mice were used in all experiments. C57Bl/6 background CD14 knockout mice were provided by Drs Mason Freeman (Harvard University) and Douglas Golenbock (University of Massachusetts), and Balb/c background LBP knockout mice by Christine Schütt (University of Greifswald) (3, 4, 20) . MD-2 knockout mice were established previously (21) .
Reagents
Salmonella minnesota Re595 Lipid A (L-0774), its derivative MPL (L-6895), and Dynasore were purchased from Sigma. Soluble mouse TLR4/MD-2 protein has been described in previous reports (5, 19) .
Antibodies
Monoclonal antibodies against mouse TLR4 (Sa15-21 and MT439) were established previously in our laboratory. AntipSyk, pIRF3 (Cell Signaling Technology) and anti-Grb2 (Santa Cruz Biotechnology) were purchased.
Plasmids
The plasmids encoding mouse TLR4-GFP, TRAM-GFP, TIRAP-GFP, TLR4-Flag, MD-2-Flag and CD14 were cloned into pMX retroviral vectors and transduced as previously described (7, 12) .
Flow cytometry
Cells were subjected to staining with biotinylated Sa15-21 followed by Streptavidin-PE or anti-CD86-PE (eBioscience). The PBS-based staining buffer included 2.5% FBS and 0.1% sodium azide. Samples were analyzed on a FACSCalibur (BD) and analyzed by using FlowJo software (Tree Star).
ELISA
TNFα in culture supernatant or serum was quantified by ELISA using DuoSet (R&D systems), according to the manufacturer's instructions.
Culture of bone marrow derived conventional dendritic cells and retroviral transduction
Mouse bone marrow cells were harvested and cultured with GM-CSF (10 ng·ml −1 ). Wild-type or F126A mutant MD-2 was transfected into MD-2 −/− derived stem cells and these were differentiated to conventional dendritic cells (cDCs). In brief, the stem cells were sampled from 5-fluorouracil-treated mice and cultured with IL-3, IL-6 and SCF. Two days later, retrovirus transduction was performed twice. cDCs were differentiated by GM-CSF in combination with puromycin selection for 10 days.
LBP reconstitution assay
Recombinant LBP from Bio Vision was added to LBP −/− serum at 2.2 μg per million DCs.
Immunoprecipitation and immunoblotting
Anti-GFP mAb, FM264, directly conjugated to 4FF-sepharose beads (GE) was prepared. Cells after stimulation were washed and lysed for 30 min on ice. Lysis buffer contains 20 mM TrisHCl pH 7.4, 150 mM NaCl with each appropriate detergent, 1% TritonX100, 1% TritonX100 plus 60 mM Octylglucoside or 1% Digitonin for TLR4, TRAM and TIRAP, respectively, supplemented with 10 μg·ml −1 aprotinin (Roche) and 10 μg·ml
leupeptin (Roche). After immunoprecipitation with anti-GFP, samples were subjected to immunoblotting against TLR4 with MT439 mAb.
In vitro dimerization detection assay
This assay was performed as described previously (19) .
Ligand injection
One hundred micrograms per 20 g mouse weight of lipid A or MPL was i.p. injected. One hour after injection, blood was sampled and the serum was subjected to ELISA.
Statistical analysis
The t-test was used to analyze results. P values under 0.05 were considered to be significant and are indicated with an asterisk.
Results
MPL is weaker than lipid A in inducing TIRAP association with TLR4/MD-2
Both MyD88-and TRIF-dependent signaling require their sorting adaptor proteins, TIRAP (9) and TRAM (11, 12) , respectively. To study activation of TRIF-biased signaling by MPL, recruitment of sorting adaptors to TLR4/MD-2 after MPL stimulation was examined. We used two Ba/F3 transfectants expressing TLR4, MD-2 and CD14 with either TIRAP-GFP or TRAM-GFP. GFP-tagged sorting adaptors were immunoprecipitated after lipid A or MPL stimulation at 1 μg·ml
, and co-precipitated TLR4 was detected by western blotting. TRAM-TLR4 association was comparably observed in lipid A and MPL-treated cells from 5 min to 2 h (Fig. 1A, top) . On the other hand, the ligand-dependent association of TIRAP with TLR4 revealed a difference between lipid A and MPL (Fig. 1A, bottom) . TIRAP association with TLR4 was detected at 5 min after stimulation with either lipid A or MPL. Lipid A-induced TIRAP association continued to be detectable up to 60 min, whereas MPL-induced TIRAP-TLR4 association rapidly became undetectable. Given that TRAM was required for TRIF signaling, this result was consistent with TRIF-biased signaling by MPL (16) .
Impaired TLR4/MD-2 dimer formation upon MPL ligation
To dissect mechanisms underlying impaired TIRAP recruitment to TLR4/MD-2, receptor dimerization was studied. We first conducted native PAGE with mouse TLR4 ectodomain/ MD-2 purified protein. Lipid A-induced dimerization of mouse TLR4/MD-2 was detected, whereas MPL-induced dimerization was undetectable (Fig. 1B) . Impaired TLR4/MD-2 dimerization by MPL was further confirmed by another in vitro assay. Ba/F3 transfectant expressing CD14, MD-2-Flag, TLR4-GFP and TLR4-Flag was explored (14) . After stimulation with lipid A or MPL, TLR4-GFP was precipitated to evaluate TLR4/MD-2 dimerization by detecting co-precipitation of TLR4-Flag. MPL was much weaker than lipid A in inducing TLR4/MD-2 dimerization ( Fig. 1C and D) . MPL-mediated TLR4/MD-2 dimerization was not delayed (Fig. 1C) , and even a larger amount of MPL failed to enhance TLR4/MD-2 dimerization as much as lipid A did (Fig. 1D) . These results demonstrated that MPL was defective in inducing TLR4/MD-2 dimerization.
The co-precipitation has been reported as a CD14-dependent phenomenon (14) , which we also tested with a CD14-lacking transfectant, which was expressing TLR4-Flag, TLR4-GFP and MD-2-Flag ( Fig. 1E and F) , to address the CD14 requirement for MPL-induced TLR4 dimerization. Consistent with a previous report (14) , TLR4-Flag was not co-precipitated with TLR4-GFP after lipid A stimulation at any time point of incubation (Fig. 1E) or any ligand concentration (Fig. 1F) . Likewise, MPL stimulation did not induce coprecipitation of TLR4-Flag with TLR4-GFP ( Fig. 1E and 1F) . These results showed that neither lipid A nor MPL has the potential to induce TLR4 co-precipitation in the absence of CD14. These indicated that MPL-induced weak TLR4 dimerization still depends on CD14.
To ask whether MPL responses do not entirely require TLR4/MD-2 dimerization, we examined MPL responses in MD-2 −/− bone-marrow-stem-cell-derived cDCs (BM-cDCs) complemented with MD-2 or MD-2 F126A mutant. The F126A mutation impairs ligand-dependent TLR4/MD-2 dimerization without any influence on ligand binding (7, 8) . MD-2 −/− cDCs complemented with either wild-type or F126A MD-2 were stimulated with lipid A or MPL, and TNFα production was evaluated by ELISA. MPL-dependent TNFα production was recovered by wild-type MD-2 but not by F126A MD-2 (Fig. 1E) . These results demonstrated that TLR4/MD-2 dimerization was induced by MPL, albeit more weakly than by lipid A.
Roles of LBP in MPL responses
To address mechanisms underlying MPL-induced weak TLR4/MD-2 dimerization, we focused on the contributions of LBP and CD14. LBP is a soluble protein mainly produced by the liver but not by cDCs themselves. LBP is necessary for LPS responses (22) . We stimulated wild-type BM-cDCs with lipid A or MPL in the presence of heat inactivated 1% serum from LBP +/+ or LBP −/− mice in vitro. TNFα production ( Fig. 2A ) was not detected in the absence of LBP. This result demonstrated a crucial role of LBP in TLR4/MD-2 responses. Since a previous report on LBP, which was published before identification of TLR4 and MD-2 as the LPS sensor, showed that LBP solely accelerates the binding of LPS to CD14 (23), we demonstrated that reconstitution of LBP protein rescued TNFα production in response to lipid A, confirming the hyporesponsiveness of the LBP −/− phenotype. As shown in Fig. 2B , rLBP was able to complement the lipid A response under LBP −/− conditions. These results indicated that LBP was indispensable for sensing MPL as well as lipid A.
Roles of CD14 in MPL responses
CD14 has a variety of roles in TLR4/MD-2 activation including ligand loading to TLR4/MD-2 (1, 14, 20) and TLR4/MD-2 internalization (2, 15). CD14-mediated TLR4-independent Syk activation is required for TLR4/MD-2 internalization 
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and subsequent TRIF-dependent signaling (15) . We first analyzed MPL responses in CD14 −/− BM-cDCs. Lipid A-dependent TNFα production was partially impaired in CD14 −/− BM-cDCs when stimulated at 10 but not 100 ng·ml −1 (Fig. 3A) . On the other hand, MPL-induced TNFα production was intact in CD14 −/− BM-cDCs (Fig. 3A) . In addition to in vitro studies, we examined in vivo TNFα production after ligand injection. As predicted from in vitro data, MPL injection induced little TNFα production in CD14 +/+ mice, whereas MPL induced a significant amount of TNFα in CD14 −/− mice (Fig. 3B) . These results demonstrated that MPL induced CD14-independent TNFα production, suggesting that CD14 in vivo may negatively regulate CD14-independent TNFα production by the presence both of soluble CD14 and membrane-bound CD14.
As previously reported (2), IFNβ mRNA induction by lipid A or MPL stimulation was abolished in CD14 −/− cells (Fig. 3C) . At 10 ng·ml . CD14 interaction with lipid A induces Syk phosphorylation, followed by CD14 internalization. IRF3 is phosphorylated downstream of TRIF signaling. Phosphorylation of Syk and IRF3 after stimulation with lipid A or MPL was studied. Both Syk and IRF3 activation was comparable between MPL-and lipid A-stimulated cells (Fig.3D) , suggesting that MPL interacted with CD14 as much as lipid A. Furthermore, MPL did not apparently have a defect in inducing TLR4/MD-2 internalization (Fig.3E) .
CD86 up-regulation does not require CD14
To study MPL-mediated activation of adaptive immune responses, up-regulation of CD86, a co-stimulatory molecule for T cells, was examined. CD86 up-regulation is dependent on TRIF-dependent signaling (13) . BM-cDCs were stimulated with lipid A or MPL, and CD86 induction was evaluated by flow cytometry. MPL induced CD86 up-regulation as much as lipid A (Fig. 4A-C) . LBP −/− BM-cDCs were impaired in CD86 up-regulation (Fig. 4A) , whereas CD14 −/− BM-cDCs did not show any alteration in CD86 up-regulation by MPL or lipid A (Fig. 4B) . CD14-independent CD86 up-regulation was not consistent with the previous report that CD14 is required for the TRIF-dependent signaling pathway (2). CD14-mediated TLR4/MD-2 internalization is thought to be indispensable for TRIF-dependent responses. Although TLR4/MD-2 was not internalized in CD14-negative cells (14) (Fig.3E) , CD86 was up-regulated by lipid A or MPL in CD14 −/− BM-cDCs. To further confirm that TLR4/MD-2 internalization was not required for CD86 up-regulation, Dynasore, a dynamin inhibitor (11), was used. CD86 up-regulation by MPL or lipid A was still observed in the presence of Dynasore (Fig. 4C) . These results demonstrated that not all the TRIF-dependent responses were activated in endosomes. CD86 up-regulation was induced by TLR4/MD-2 on the cell surface.
Discussion
Up-regulation of the co-stimulatory molecule CD86 is one of the initiators for adaptive immune activation in innate immune responses and is a key response, considering MPL's clinical usage as adjuvant. Previous studies showed that CD86 is up-regulated by a MyD88-independent, TRIF-dependent pathway (13) . Recent studies on TLR4/MD-2 responses have focused on the requirement of precise subcellular positioning of TLR4/MD-2 and downstream signaling molecules for each TLR4 response. Plasma membrane, endosomes, and mitochondria are identified as the activation platform for inflammatory cytokines (9, 15) , IFNβ (11, 12) and reactive oxygen species (24) , respectively. It is believed that MyD88-and TRIFmediated responses are induced at the plasma membrane or in endosomes, respectively. Whereas the requirement of TLR4/ MD-2 internalization to endosomes for TRIF-mediated signaling activation has been already reported (11, 12) , this study showed that CD86 is induced by TLR4/MD-2 at the plasma membrane. In other words, TRIF signaling was activated not only in endosomes but also at the plasma membrane as depicted in Fig. 5 . TLR4/MD-2 internalization requires cell surface CD14 (15) and is inhibited by Dynasore (11) . Here we demonstrated that cell surface CD86 up-regulation did not require CD14 and was not inhibited by Dynasore treatment. Recruitment of TIRAP is dependent on its interaction with phosphatidylinositol 4,5-biphosphate (PIP2) (9) , whereas that of TRAM depends on its myristoylation (11) . A majority of PIP2 is localized in the plasma membrane rather than in endosomes. PIP2 is enriched in plasma membrane microdomains (25) , where MyD88-signaling is likely to be activated. Given that CD86 induction is not dependent on MyD88, CD86 up-regulation is likely to be induced by TLR4/MD-2 in another plasma membrane microdomain where PIP2 is excluded.
According to the crystal structure of TLR4/MD-2 plus ligand (6), the negative charge of the 1-phosphate group in lipid A, which is lacking in MPL, contributes to interaction with lysine at the 388th residue (K388) on adjacent TLR4, which comes closer after TLR4/MD-2 dimer formation (6) . The lack of chargedependent interaction with K388 is likely to weaken TLR4/MD-2 dimerization during MPL recognition. Interestingly, both lipid A-induced tight TLR4/MD-2 dimerization and MPL-induced weak dimerization depend on CD14 (14) . CD14-independent TLR4 activations were observed in TNFα production and upregulation of CD86. Considering that both the ectodomain (6) and cytoplasmic portion (26) of TLR4 have been reported as having an essential role for its activation, the 'dimerization' shown in this study may be better regarded as 'clustering'. Of note, native PAGE detected the TLR4/MD-2 dimerization that is dependent on cell surface CD14 in another assay detecting homotypic interaction of TLR4/MD-2 by its co-precipitation. Lipid A at as high as 1 μg·ml −1 or more induced TLR4/MD-2 dimerization in the co-precipitation assay, but not in native Although that MPL failed to activate CD14-dependent responses at the plasma membrane, MPL did activate CD14-dependent TLR4/MD-2 internalization and subsequent IFNβ induction. TLR4/MD-2 internalization is dependent on CD14 signaling mediated by a tyrosine kinase Syk (15) . We found that MPL induced Syk phosphorylation as much as lipid A. This result suggested that MPL was comparable to lipid A in activating CD14, whereas MPL activated TLR4/ MD-2 via a CD14-independent manner. These results suggested CD14-independent MPL loading onto TLR4/MD-2. 5 . Model depicting cascades of TLR4/MD-2 activation. LBP first captures and transports LPS to the plasma membrane localized TLR4/ MD-2 by either a CD14-dependent or a CD14-independent manner. CD14-dependently activated TLR4/MD-2 initiates signals through TIRAPMyD88 to activate inflammatory cytokine expression with tight dimer formation. CD14 then transports TLR4/MD-2 to endosomes, where TRAM-TRIF signaling can lead to IFNβ. In contrast, CD14-independently activated TLR4/MD-2 initiates signals through both TIRAP-MyD88 and TRAM-TRIF at the plasma membrane, leading to TNFα and CD86 up-regulation, respectively. On the other hand, MPL has a defect in the ligand transfer from CD14 to TLR4/MD-2. Due to the lack of recruitment of CD14, MPL does not form tight TLR4/MD-2 dimers and is impaired in TNFα production. Besides, CD14-independent TLR4/MD-2-initiation and CD14-mediated TLR4/MD-2 internalization are left in the MPL responses; these are important for up-regulation of cell surface CD86 and IFNβ induction, respectively. Downloaded from https://academic.oup.com/intimm/article-abstract/26/6/307/675632 by guest on 08 February 2019
Our results illustrated that low toxicity and biased activation of MPL can be ascribed to the lack of CD14-initiated inflammatory responses at the plasma membrane such as TNFα production. Moreover, another lipid A derivative CRX-527 is also described as a CD14-independent TLR4 ligand (27) . CRX-527 lacks the 1-phosphate group, same as MPL. This insight also indicated that this phosphate group determines the dependency of CD14. Finally, we believe that this differential requirement of LBP and CD14 in MPL-mediated TLR4 activation provides a clue to harness the detoxified TLR4 activation and could be beneficial for clinical vaccination. 
